It can be uncomfortable to talk about IBS, but doing so can help you find support and feel less alone. Deciding who to tell and how much to share can help get the conversation started. Irritable bowel ...
Findings showed 30% of patients taking linaclotide 145mcg achieved the primary endpoint of combined responder. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the ...
Verywell Health on MSN
5 IBS-C triggers that aren’t food
Medically reviewed by Robert Burakoff, MD Key Takeaways Diet is a major trigger for IBS symptoms, but other triggers include ...
SAN DIEGO -- The oral full-spectrum microbiome drug EBX-102-02 was well tolerated with mostly mild gastrointestinal adverse events and a trend toward less patient-reported pain and straining in those ...
For millions of Americans, bathroom trips bring anxiety rather than relief. Irritable bowel syndrome with constipation (IBS-C) impacts approximately one-third of all IBS cases, causing physical ...
Dear Dr. Roach: I'm a young adult male who has been diagnosed with irritable bowel syndrome with constipation (IBS-C). Until this diagnosis, I had never even heard of the condition. A colonoscopy and ...
Verywell Health on MSN
50 foods to eat and avoid with IBS-C
Medically reviewed by Robert Burakoff, MD Key Takeaways To manage IBS-C, enjoy low-FODMAP foods with soluble fiber while avoiding ultra-processed, high-FODMAP, and insoluble fiber foods.Some higher ...
A recent survey weighed the needs and experiences of IBS-C patients with the challenges healthcare providers face when treating them. Using an online questionnaire, the researchers surveyed patients ...
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, presented new data from four scientific abstracts during the American College of ...
How do you help patients with soft stool that won't move through manage idiopathic constipation? Join Drs Lin Chang and Anthony Lembo as they discuss nuanced decision-making around treating IBS ...
Ardelyx, Inc. announced that it will present data on its innovative IBSRELA® (tenapanor) at the Digestive Disease Week Conference in San Diego from May 3-6, 2025. IBSRELA is FDA-approved for treating ...
Salix Pharmaceuticals has identified a blockage in the irritable bowel syndrome (IBS) care pathway. Based on an online survey of 724 people, the manufacturer of a pair of IBS treatments thinks more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results